# Final Area Chair Meta-Review

## Decision

**Recommendation: Weak Accept**

**Confidence: 4/5**

I based this decision on the current 35-page PDF, weighting `R10_review.md` most heavily and using the older reviews only to identify issues that might have survived revision. I did not average scores across versions. I also calibrate to the GenAI4Health Research Paper track rather than the NeurIPS main-conference bar: the track expressly permits work in progress when the current evidence supports the central claim, and the 2025 venue survey found headline multi-seed results in only one of 17 accepted research papers while also finding accepted negative-result, simple-baseline, and implementation-postmortem papers. Single-run pretraining is therefore a limitation here, but not by itself a reason to reject.

## 1. Summary of the submission and central claim

The paper studies target placement for 3D retinal-OCT I-JEPA pretraining. Six policies continue from one shared epoch-25 checkpoint: unguided rectangles (RANDOM), rectangles biased toward a MIRAGE-predicted retinal envelope (ENVELOPE), a segmentation-free intensity-centroid band (CENTROID), two segmentation-shaped policies (ANATOMY-V1/V2), and a coverage-seeking policy (COVER). Evaluation is by frozen mean-pooled linear probes for glaucoma on the patient-disjoint FairVision test set of 3,000 volumes.

In the reported continuations, ENVELOPE exceeds RANDOM by +0.0120 AUC at epoch 50 and remains above it at epochs 75 and 100; CENTROID exceeds RANDOM by +0.0109 at epoch 100 and is the highest observed epoch-100 endpoint. ANATOMY-V2 is +0.0013 from RANDOM at epoch 50 with a paired interval spanning zero, then is -0.0111 below it at epoch 75. COVER reaches epoch 100 but has a post-placement truncation defect, so it did not deliver the aggressive anatomical coverage it was intended to test (Table 1; Sections 5.1–5.2; Appendix G).

The authors' broad message is that anatomy helps determine where to aim prediction targets, but greater anatomical precision or coverage does not add. The evidence supports a narrower central claim: **for these particular post-fork continuations, retina-biased placement of ordinary rectangles and a segmentation-free centroid band outperform unguided masking, while the tested anatomy-shaped implementations show no uniform additional advantage.** It does not identify a causal effect of target shape or amount covered.

## 2. Consensus that survives checking the current PDF

1. **The within-rectangle comparison is the strongest contribution.** RANDOM and ENVELOPE use the same nominal rectangle shapes, scales, counts, ancestor, schedule, effective batch size, and probe protocol; the policy changes their placement. Both ENVELOPE and CENTROID remain above RANDOM at all three reported matched checkpoints (Sections 3.2 and 5.1; Appendix N). Placement also changes realized overlap, mask ratio, and context, so this is a useful policy comparison rather than a pure mechanism experiment.

2. **The cross-family anatomy/coverage interpretation is not identified.** ANATOMY-V2 changes target shape, collation, delivered mask ratio, retained context, and predictor loss slots together. COVER is defective and was not rerun. The paper now says H3 is not identified and does not claim that irregular target shape is harmful, which is correct (Table 2; Sections 5.2 and 6; Appendices D and G). The title and several headings remain stronger than that analysis.

3. **The reported uncertainty is conditional on fixed trained encoders.** The paired subject bootstrap and correlated-ROC tests are appropriate for the same 3,000 cases, but they do not estimate post-fork optimization or probe-seed variation. Repeated checkpoints are not independent retrainings. The paper states this explicitly (Section 6; Appendix B).

4. **Adaptive reuse of the test split is a genuine weakness.** Policies, checkpoints, analyses, and stopping horizons followed repeated inspection of the same split. Multiplicity correction over the final displayed families cannot account for that research-program-level selection. The current paper appropriately calls its intervals descriptive rather than confirmatory, but an untouched cohort remains absent (Sections 4 and 6).

5. **Clinical and external validity are narrow.** The study covers one public OCT cohort, one disease label, one ancestor, and one segmentation ecosystem. The shared-threshold sensitivity result is not at a shared realized false-positive rate, and the paper now says so. The smaller race strata and intersectional cells are underpowered; no model is clinically validated (Appendices E, E.1, K, and L).

6. **The fixed-model technical audit is unusually strong.** Delivered mask geometry is measured rather than assumed; fp32 re-probing makes numerical precision an implausible explanation; re-encoding from released weights on different hardware reproduces the reported endpoint closely; and the appendix now includes estimator diagnostics and explicit data provenance (Sections 5.6; Appendices D, L, O, and P). These controls do not solve the design limitations, but they make the conditional result credible.

## 3. Reviewer disagreements, resolved from the current paper

### Is one continuation per policy fatal?

The earlier area-chair review called this “acceptance-determinative,” whereas R10 treats it as important but not independently disqualifying. R10 applies the correct venue bar. One continuation cannot establish an expected policy ranking, but GenAI4Health's own record shows that multi-seed headline training is exceptional rather than required, including among accepted method papers. The current paper uses run-level language in the Abstract and Section 6, reports the same signs at three checkpoints, and does not present the bootstrap as seed uncertainty. I therefore treat `n=1` as a material limit on generalization, not a near-automatic rejection.

### Does ANATOMY-V2 contradict itself across epochs?

No. “Does not separate from RANDOM” refers to the matched epoch-50 result; “falls below it” refers to epoch 75. Both statements are true at their stated scopes, and epoch 100 is explicitly unmeasured. Selective stopping after seeing the epoch-75 deficit remains a weakness, but there is no numerical contradiction (Table 1; Sections 4, 5.1, and 6).

### Is the test set held out or used for development?

Both, at different scopes. Section 4 says no test volume is used to fit or select the **probe head**, which is selected on validation. The same sentence says the broader choices of policy, checkpoint, analysis, and stopping horizon followed repeated test inspection. The former is a head-fitting statement; the latter is an adaptive-study-design limitation. Calling these sentences contradictory is incorrect, although “held-out” should not be used without the narrower qualifier.

### Is H2 directly tested?

Yes descriptively, but not causally. Section 5.1 gives the direct matched-epoch ANATOMY-V2 minus ENVELOPE contrast as -0.0107 with interval [-0.0167, -0.0046], and also reports the opposite-direction ANATOMY-V1 comparison at epoch 30. These different implementations and epochs rule out a **uniform** advantage for anatomical precision among the runs shown. They do not isolate precision or shape because the training budgets and collation differ (Table 2).

### Does the operating-point analysis claim equal false-positive rates?

No. Appendix K explicitly states that one numeric threshold is transferred across separately fitted heads, that achieved specificity changes, and that the comparison is at a shared threshold rather than a shared realized false-positive rate. The sensitivity analysis is exploratory and clinically insufficient, but the earlier allegation that the paper claims a gain “at the same false-positive rate” is stale.

### Are the probe counts contradictory?

The current Appendix A explains the counts: 37 table rows, 31 valid probes, 23 valid probes with joined subgroup metadata, and 19 with the complete race summaries used for the scatter. The 23-probe gap trend and 19-probe scatter use different stored summaries by construction. Listing the four omitted scatter points would improve auditability, but the counts are no longer an unreconciled contradiction.

## 4. Reviewer errors corrected

The following criticisms are factually wrong about the current PDF:

1. **P14:** “The paper violates the stated nine-page main-text limit” and “the primary results table contains four red `pending` cells.” The current body ends on page 9, References begins on page 10, and Table 1 uses an em dash for unrun ANATOMY-V2 epoch 100 rather than pending result cells.

2. **P18:** the paper says another 25 epochs “would have deepened” the ANATOMY-V2 deficit. The current Section 4 says the opposite: “a trajectory can recover,” and epoch 100 is “unmeasured, not known to be worse.”

3. **P17/P18:** “The paper does not report the required ANATOMY-V2-versus-ENVELOPE paired contrast.” The direct epoch-50 contrast and interval are in Section 5.1.

4. **P18:** the 5% label results are 0.8108 versus 0.7925 under an unmatched full-batch protocol. The current Appendix I uses the primary minibatch AdamW/warmup-cosine protocol and reports 0.8335 for CENTROID and 0.7839 for RANDOM. Its full-data null/CENTROID check is explicitly distinguished from the four-arm comparison.

5. **CONFIRM:** the “within 0.0003” reproduction statement is false for ENVELOPE and COVER. The current text scopes 0.0003 only to RANDOM and CENTROID and separately gives the four-arm maximum discrepancy as 0.0009 (Section 5.4; Appendix I). These are compatible statements over different sets.

6. **P17/P18:** the Discussion ignores the epoch-75 ANATOMY-V2 deficit or calls it indistinguishable everywhere. The Abstract, Introduction, Table 1, setup, Discussion, and Conclusion now distinguish the unresolved epoch-50 result from the negative epoch-75 result.

7. **P17:** the Results falsely call COVER the only segmenter-driven policy reaching epoch 100. The current sentence says COVER is the only policy using the segmenter to choose **how much to hide**; ENVELOPE uses it for location. That narrower statement is true.

8. **R10:** “There is one clear count contradiction” between 23 race-gap probes and 19 scatter probes. Appendix A now supplies the subset explanation quoted above. The remaining issue is documentation of membership, not contradictory arithmetic.

9. **Several earlier reviews:** intersectional analysis is absent and multiplicity claims assert that every race or severity gain is established. The current Appendix E.1 reports race-by-sex cells, while Table 8 uses one simultaneous 10-contrast family and withdraws claims for moderate, severe, Black, and Asian intervals that include zero. The intersectional deltas still lack paired intervals, and the paper says so.

The current revisions also remove the former ORACLE display name, duplicated reference, stale precision caption, and obsolete COVER chronology. Those earlier findings should receive no weight in this decision.

## 5. Genuinely outstanding weaknesses, ranked

### Weaknesses requiring new experiments

1. **Untouched evaluation after adaptive test reuse.** This is the strongest remaining threat. A locked comparison on an untouched temporal, scanner, or population cohort is needed for confirmatory inference.

2. **A matched anatomy/coverage intervention.** If “not how much to cover” remains a central claim, a corrected COVER arm or anatomy-shaped arm must match delivered mask ratio, context, loss slots, target count, guide provenance, collation, and endpoint. The present experiment cannot identify amount or shape.

3. **Continuation-level replication.** The planned two additional seeds for RANDOM, ENVELOPE, and CENTROID would test whether the clean rectangle-family signs survive post-fork optimization noise. This is not required for a workshop-level exploratory report, but it is required for a policy expectation.

4. **Broader and clinical validation.** A second task/cohort and model-specific validation-selected thresholds evaluated once on untouched data are needed before any clinical or general medical-masking claim. Direct characterization of MIRAGE quality on FairVision would also clarify the anatomy-arm interpretation.

### Weaknesses fixable by writing

1. **Narrow the title and causal wording.** “Not how much to cover,” “identical in every other respect,” and “masking policy the only moving variable” overstate a design that the same paper says does not identify H3. The title, Abstract, Section 5.2 heading, and Conclusion should describe implemented run-level outcomes, not an isolated mechanism.

2. **Repair the fairness scope statements.** Appendices E and L say no subgroup calibration is reported, while Appendix K gives race-stratified ECE values. “The disparity is not introduced by any policy” is also too strong: unchanged worst-group identity does not establish the origin or constancy of a disparity.

3. **Finish artifact terminology and subset documentation.** Define the residual “BLOB” label, list which probes are absent from the 19-probe race scatter and 18-arm intersectional artifact, and replace live-document `PENDING` language with “not run/not reported” where no result belongs in the submission.

4. **Soften secondary mechanism headings.** Label-scarcity concentration, background targets being “not wasted,” and attribution-based error mechanisms are suggestive observations; the paper itself notes that the required interaction tests or controls were not run.

Candor makes these boundaries easier to identify but is not evidence. I have not credited disclosure as validation, nor penalized the COVER defect twice: it weakens the amount/coverage claim once and contributes value only as an implementation postmortem.

## 6. Minimum evidence that would change my view

Because I am narrowly on the acceptance side, the minimum adverse evidence that would reverse the decision is the paper's own precommitted failure case: a sign reversal in a paired epoch-50 ENVELOPE-minus-RANDOM or CENTROID-minus-RANDOM continuation, or a three-continuation range spanning zero. That would remove the stability needed for even the narrow workshop claim and move me to Weak Reject.

Conversely, same-sign effects across all three planned continuations would move me toward Accept; adding a single locked evaluation on an untouched cohort would address the more serious adaptive-selection concern. Retaining the present causal title would additionally require the matched anatomy/coverage intervention described above.

## 7. Final recommendation

**Weak Accept, confidence 4/5.**

Three considerations decide the recommendation. First, the clean, fixed-run rectangle-placement result is supported by matched checkpoints, paired case-level analysis, precision controls, and artifact reproduction. Second, the venue's demonstrated bar does not make single-run pretraining, a negative result, one dataset, or work in progress disqualifying; the previous area-chair decision applied a main-conference replication standard that is not supported by GenAI4Health practice. Third, the adaptive test reuse and unidentified amount/shape mechanism prevent a stronger recommendation and require claim narrowing, but they do not erase the useful, explicitly run-level empirical observation. The appropriate publication record is an exploratory OCT masking-policy study and implementation audit, not proof that anatomy amount or target shape is causally irrelevant.
